Downregulation of C3 and C4A/B complement factor fragments in plasma from patients with squamous cell carcinoma of the penis

International Braz J Urol

Volumn 38, Issue 6, 2012, Pages 739-749

  Ornellas, Paulo ^a   Ornellas, Antonio Augusto ^b,c   Chinello, Clizia ^d   Gianazza, Erica ^d   Mainini, Veronica ^d   Cazzaniga, Marta ^d   Pereira, Denise Abreu ^a   Sandim, Vanessa ^a   Cypriano, Ana Sheila ^a   Koifman, Leandro ^c   Da Silva, Paulo Cesar Barbosa ^b   Alves, Gilda ^a   Magni, Fulvio ^d  

^a Laboratory of Applied Genetics   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c Serviço de Urologia Hospital Mário Kröeff   (Brazil)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Carcinoma; Complement c3b inactivator proteins; Penis; Penis cancer; Plasma; Proteomics; Squamous cell

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; DOWN REGULATION; HUMAN; IMMUNOLOGY; MALE; MASS SPECTROMETRY; MIDDLE AGED; PATHOLOGY; PENIS TUMOR; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMPLEMENT C3; COMPLEMENT C4A; COMPLEMENT C4B; DOWN-REGULATION; HUMANS; MALE; MIDDLE AGED; PENILE NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, PROTEIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84874818488     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/1677-553820133806739     Document Type: Article

References (36)

1. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol. 2004; 5: 240-7.
2. Ornellas AA, Kinchin EW, Nóbrega BL, Wisnescky A, Koifman N, Quirino R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol. 2008; 97: 487-95.
3. Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol. 1993; 72: 817-9.
4. Soria JC, Fizazi K, Piron D, Kramar A, Gerbaulet A, Haie-Meder C, et al.: Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol. 1997; 8: 1089-98.
5. Lopes A, Bezerra AL, Pinto CA, Serrano SV, de MellO CA, Villa LL. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol. 2002; 168: 81-6.
6. Ornellas AA, Nóbrega BL, Wei Kin Chin E, Wisnescky A, da Silva PC, de Santos Schwindt AB. Prognostic factors in invasive squamous cell carcinoma of the penis: analysis of 196 patients treated at the Brazilian National Cancer Institute. J Urol. 2008; 180: 1354-9.
7. Abi-Aad AS, deKernion JB. Controversies in ilioinguinal lymphadenectomy for cancer of the penis. Urol Clin North Am. 1992; 19: 319-24.
8. Alpantaki K, Tsiridis E, Pape HC, Giannoudis PV. Application of clinical proteomics in diagnosis and management of trauma patients. Injury. 2007; 38: 263-71.
9. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al.: Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006; 7: 230-40.
10. Sarto C, Proserpio V, Magni F. Insight on renal cell carcinoma proteome D.S. Sayed (ed.), Cancer Proteomics From Bench to Bedside, Humana Press, Totowa, NJ. 2008; pp. 121-37.
11. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004; 15: 24-30.
12. Bosso N, Chinello C, Picozzi SC, Gianazza E, Mainini V, Galbusera C, et al.: Human urine biomarkers of renal cell carcinoma evaluated by ClinProt. Proteomics Clin Appl. 2008; 2: 1036-46.
13. Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, et al.: Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics. 2006; 6: 697-708.
14. Chang JT, Chen LC, Wei SY, Chen YJ, Wang HM, Liao CT, et al.: Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry--plasma peptidomes from nasopharyngeal cancer patients for example. Clin Biochem. 2006; 39: 1144-51.
15. Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples. Laryngoscope. 2008; 118: 61-8.
16. Chinello C, Gianazza E, Zoppis I, Mainini V, Galbusera C, Picozzi S, et al.: Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on Clin-Prot technique. Urology. 2010; 75: 842-7.
17. Ketterlinus R, Hsieh SY, Teng SH, Lee H, Pusch W. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques. 2005; (Suppl): 37-40.
18. Holland JH. Adaptation in Natural and Artificial Systems. Ann Arbor, MI: University of Michigan Press. 1975.
19. Vapnik V. Statistical Learning Theory. New York, NY, Wiley. 1998; pp. 1-736.
20. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988; 240: 1285-93.
21. Scheiner MA, Campos MM, Ornellas AA, Chin EW, Ornellas MH, Andrada-Serpa MJ. Human papillomavirus and penile cancers in Rio de Janeiro, Brazil: HPV typing and clinical features. Int Braz J Urol. 2008; 34: 467-74; discussion 475-6.
22. Muneer A, Kayes O, Ahmed HU, Arya M, Minhas S. Molecular prognostic factors in penile cancer. World J Urol. 2009; 27: 161-7.
23. Shen Y, Tolić N, Liu T, Zhao R, Petritis BO, Gritsenko MA, et al.: Blood peptidome-degradome profile of breast cancer. PLoS One. 2010; 5: e13133.
24. Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett. 2007; 111: 6-13.
25. Taneja S, Ahmad I, Sen S, Kumar S, Arora R, Gupta VK, et al.: Plasma peptidome profiling of acute hepatitis E patients by MALDI-TOF/TOF. Proteome Sci. 2011; 9: 5.
26. Afonso LA, Moyses N, Alves G, Ornellas AA, Passos MR, Oliveira Ldo H, et al. Prevalence of human papillomavirus and Epstein-Barr virus DNA in penile cancer cases from Brazil. Mem Inst Oswaldo Cruz. 2012; 107: 18-23.
27. Campo MS, Graham SV, Cortese MS, Ashrafi GH, Araibi EH, Dornan ES, et al.: HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology. 2010; 407: 137-42.
28. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem. 2000; 275: 16666-72.
29. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA, Armitage NC. Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother. 2003; 52: 638-42.
30. Blok VT, Daha MR, Tijsma OM, Weissglas MG, Van Den Broek LJ, Gorter A. A possible role of CD46 for the protection in vivo of human renal tumor cells from complementmediated damage. Lab Invest. 2000; 80: 335-44.
31. Campos MM, de Souza MH, Pires V, Scheiner MA, Esteves EB, Ornellas AA. Clinical implications of natural killer cytotoxicity in patients with squamous cell carcinoma of the penis. Nat Immun. 1998; 16: 256-62.
32. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991-8.
33. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006; 90: 1-50.
34. Bronte V, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, et al. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest. 2006; 35: 327-57.
35. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25: 267-96.
36. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006; 6: 715-27.